Company Overview - Scholar Rock is a biotech company celebrating its 15th anniversary in 2023, founded in 2012 with innovative technology from Tim Springer and Len Zon's lab [2] - The company focuses on developing antibody technology to inhibit difficult-to-target growth factors and proteins in the body [2] Key Achievements - Scholar Rock's most significant success has been the inhibition of myostatin, leading to the first positive pivotal trial targeting myostatin after three decades of attempts by the pharma and biotech industries [3] - The trial results were reported at the end of 2024, and the company is currently awaiting FDA and EMA approval for the product launch this year [3]

Scholar Rock FY Conference Summary Company Overview - **Company**: Scholar Rock (NasdaqGS:SRRK) - **Industry**: Biotechnology - **Foundation**: Established in 2012, celebrating its fiftieth anniversary in 2026 - **Focus**: Development of antibody technology to inhibit difficult growth factors, particularly myostatin [2][3] Core Points and Arguments - **Myostatin Inhibition Success**: Scholar Rock has achieved a significant milestone by successfully inhibiting myostatin, leading to the first positive pivotal trial for treating spinal muscular atrophy (SMA) after decades of attempts by the industry [3] - **Regulatory Approvals**: The company is awaiting FDA and EMA approval for its lead asset, apitegromab, with plans for commercial launches in the U.S. and Europe in 2026 [5][49] - **Debt Instrument**: Scholar Rock announced a $550 million debt instrument to fund operations, with an additional $100 million expected to be drawn down by the end of the quarter [5][9] - **Clinical Trials**: The company is advancing its pipeline with key Phase 2 clinical trials, including: - OPAL study for apitegromab combined with gene therapy for infants and toddlers with SMA [6] - FORGE study for facioscapulohumeral muscular dystrophy (FSHD) involving 60 patients [59][61] Financial Position - **Cash Balance**: Ended the year with a cash balance of $368 million before the additional $100 million drawdown [9] - **Priority Review Voucher (PRV)**: Scholar Rock qualifies for a rare pediatric disease priority review voucher, expected to be monetized upon approval, with a value ranging between $150 million and $200 million [11][33] Market Strategy - **Global Expansion**: Plans to build a 50-country operating platform, targeting approximately 35,000 patients with SMA, with a focus on Germany as the first European market post-EMA approval [49][50] - **Patient Assistance Programs**: Launching "Scholar Rock Supports" and "Life Takes Muscle" disease education programs to assist patients and families [16][17] Regulatory Challenges - **Compliance Issues**: The delay in approval for apitegromab is due to compliance issues at the fill-finish facility owned by Novo Nordisk, which has affected the timeline for resubmission [13][27] - **Resubmission Timeline**: The company anticipates a Class 2 resubmission for FDA review, which could take up to six months, but is hopeful for a quicker turnaround based on previous experiences [29][32] Innovation and Future Directions - **Subcutaneous Formulation**: Development of a subcutaneous version of apitegromab is underway, with plans to stage discussions with regulators post-approval of the IV formulation [52][57] - **Focus on FSHD**: The rationale for targeting FSHD with apitegromab is based on the success in SMA and the potential to address muscle dysfunction in this patient population [61][64] Additional Insights - **KOL Engagement**: Ongoing discussions with key opinion leaders (KOLs) in the SMA community have been positive, highlighting the need for muscle-targeted therapies [17][19] - **Market Access in Germany**: Germany is expected to be the first country for launch in Europe due to established access and reimbursement processes [45][49] This summary encapsulates the key points discussed during the Scholar Rock FY Conference, highlighting the company's strategic direction, financial health, regulatory challenges, and innovative approaches in the biotechnology sector.

Summary of Scholar Rock Conference Call Company Overview - **Company**: Scholar Rock (NasdaqGS:SRRK) - **Focus**: Development of Apitegromab, a muscle-targeted therapy for Spinal Muscular Atrophy (SMA) Key Points Industry Context - The conference highlighted the challenges faced by biotech companies, particularly in drug development and regulatory compliance, with a specific focus on the manufacturing issues related to the Catalent Novo facility [6][7][8]. Apitegromab Development - **Phase 3 Trial**: Scholar Rock announced positive results from the phase 3 SAPPHIRE trial involving 188 patients, achieving statistically significant improvements in motor function for SMA patients [6]. - **Regulatory Timeline**: The company filed for approval in January 2025, received priority review, and had an action date set for September 22, 2025. However, a complete response letter was issued due to compliance issues at the manufacturing facility [7][14]. Manufacturing and Compliance Issues - The compliance issue was specifically related to the third-party fill-finish manufacturing facility in Bloomington, Indiana, which is now owned by Novo Nordisk [7][10]. - Following a Type A meeting with the FDA, there has been a positive progression in communication and remediation efforts at the facility, with expectations for a formal re-inspection soon [11][12][13]. Resubmission and Launch Plans - Scholar Rock reaffirmed its guidance for a BLA resubmission and U.S. launch in 2026, contingent on the successful re-inspection of the manufacturing facility [14][25]. - The company is also working on a second fill-finish facility to ensure redundancy in its supply chain, which is expected to support the 2026 launch [19][20]. Supply and Inventory Management - Scholar Rock has tens of thousands of vials of Apitegromab ready for the SMA community, which were manufactured before the compliance issues arose [22][23]. - The company is confident that the existing inventory will meet initial demand upon approval, with additional supply expected from the second facility [25]. Commercial Readiness - The commercial team has been actively preparing for the launch, including disease awareness campaigns and building relationships with treatment centers and payers [32][33]. - A patient assistance program, Scholar Rock Supports, has been established to help patients navigate the reimbursement process [35]. Global Market Opportunity - The company anticipates a significant global market for Apitegromab, with expectations of a balanced distribution of sales between the U.S., Europe, and other regions [43][46]. - There are approximately 35,000 patients globally who have received SMN-targeted therapies, indicating a robust market opportunity for Apitegromab [46]. Future Development Plans - Scholar Rock is exploring additional formulations and indications for Apitegromab, including subcutaneous delivery options and new therapies like SRK-439, a myostatin inhibitor [52][53]. Financial Position - The company announced a new loan of up to $550 million to support its operations and pipeline without diluting equity, maintaining a strong balance sheet with $368 million at year-end [57][58]. Conclusion - Scholar Rock is navigating significant regulatory and manufacturing challenges but remains optimistic about the approval and launch of Apitegromab in 2026. The company is also strategically positioning itself for future growth in the neuromuscular disease space.

Scholar Rock (NasdaqGS:SRRK) FY Conference Summary Company Overview - Scholar Rock is focused on developing innovative therapies targeting muscle-related diseases, particularly Spinal Muscular Atrophy (SMA) through its anti-myostatin pipeline, including the drug apitegromab [3][4] Key Value Creation Milestones - The company anticipates a transformative year in 2026 with the expected regulatory approvals for apitegromab in the US and Europe, aiming to establish a commercial presence in 50 countries [4][19] - Plans to develop apitegromab and a second myostatin inhibitor, SRK-439, for various severe and rare neuromuscular disorders [5][6] Regulatory and Manufacturing Updates - The initial launch of apitegromab was expected in 2025 but faced delays due to compliance issues at the manufacturing facility in Indiana, owned by Novo Nordisk [12][13] - The FDA granted a priority review for the drug, with an action date of September 22, 2025, but a complete response letter was received due to manufacturing facility compliance issues [12][14] - Positive progress has been made in remediating the facility, with a successful Type A meeting with the FDA and ongoing inspections [16][17] - The company is also preparing a second fill-finish facility to ensure supply chain robustness, which could support a 2026 launch even if the Indiana facility inspection does not go as planned [18][45] Market Opportunity and Pricing Strategy - Scholar Rock sees a multi-billion dollar opportunity in the SMA market alone, with a patient population of approximately 35,000 globally [6][50] - Pricing strategy will consider the rarity and severity of SMA, the impact of the drug on motor function, and the competitive landscape of existing therapies [51][52] Launch Strategy and Patient Engagement - The company expects robust demand for apitegromab, particularly from patients currently on therapy, with over 90% of trial participants remaining in long-term studies [53][54] - Initial launch uptake may be tempered by prior authorization requirements and medical policies from payers, but the company is optimistic about converting enrollment forms into reimbursed patients over time [56][57] Future Developments - Scholar Rock is also exploring a subcutaneous formulation of apitegromab and a next-generation myostatin inhibitor, SRK-439, which shows promise in early trials [58][61] - The company has initiated a Phase 2 study for Facioscapulohumeral Muscular Dystrophy (FSHD), with plans to dose patients later this year [64][65] Conclusion - Scholar Rock is positioned to become a significant player in the biotech space with its innovative therapies targeting muscle diseases, particularly SMA, while navigating regulatory challenges and preparing for a robust market entry in 2026 [4][19][56]

Core Viewpoint - The company reported a net loss per common share of $0.76 for the quarter ended December 31, 2025, which is an increase from a net loss of $0.61 per common share for the same quarter in 2024 [1]. Financial Results - The net loss per common share for Q4 2025 was $0.76, compared to $0.61 for Q4 2024 [1].

Core Insights - Scholar Rock is preparing to resubmit the biologics license application (BLA) for apitegromab following a successful FDA reinspection of the Catalent Indiana facility, with a targeted U.S. launch in 2026 [2][6][12] Regulatory Updates - The FDA issued a warning letter to the Catalent Indiana facility after a Type A meeting in November, but subsequent meetings indicated no additional requests for the remediation plan [1] - The FDA plans to conduct a site reinspection after routine manufacturing activities resumed in late February [1] - The compliance status of the Catalent Indiana site is the sole issue affecting the approval of the BLA [2][6] Financial Position - Scholar Rock ended 2025 with $368 million in cash and secured a new debt facility of up to $550 million, with staged draws tied to milestones [4][20] - The company plans to monetize a Priority Review Voucher to strengthen its balance sheet further [4][20] Commercial Infrastructure - The company has developed a commercial infrastructure, including specialty pharmacy access and a home-infusion network with over 10,000 affiliated nurses [5][12] - Initial access and reimbursement challenges are anticipated, particularly related to J-codes and Medicaid processes [5][12] Pipeline Developments - Scholar Rock is advancing a second fill-finish facility to support future commercial demand, with engineering runs underway [8][9] - The company is also progressing in its anti-myostatin pipeline, including ongoing studies for apitegromab in infants and toddlers [15][19] European Market Strategy - The marketing authorization application (MAA) review for apitegromab is ongoing with the European Medicines Agency (EMA), and a decision is expected in mid-2026 [11][12] - Preparations for a European launch include establishing local leadership and progressing reimbursement planning [14]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported operating expenses of $91.9 million, including $90.4 million in non-cash stock-based compensation, while excluding stock-based compensation, operating expenses were $72.5 million [26] - For the full year 2025, operating expenses totaled $384.6 million, with $75.6 million in non-cash stock-based compensation, and $309 million when excluding stock-based compensation [27] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [11][27] Business Line Data and Key Metrics Changes - The company is focused on the launch of apitegromab, the world's first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [4][29] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase I studies [10][20] Market Data and Key Metrics Changes - The SMA market is currently valued at nearly $5 billion in global annual sales, with a significant unmet need for muscle-targeted therapies as 95% of patients continue to experience muscle weakness [21][22] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [22][23] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [4][12] - The company is building a 50-country operating platform in Europe and enhancing its commercial capabilities to support the launch of apitegromab [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, reaffirming guidance for BLA resubmission and U.S. launch in 2026 [7][29] - The company is optimistic about the potential of its anti-myostatin pipeline and the significant opportunity to serve patients with SMA and other neuromuscular diseases [12][21] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D priorities, with $100 million immediately available for use [11][28] - The company is prepared to pivot to a second fill-finish facility if necessary, which would de-risk its supply chain for U.S. and EU launches [76] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management indicated that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [33][34] Question: What happens if the backup facility is needed? - Management believes that whether it is a supplemental BLA or a fallback to the backup facility, the timing would not be significantly altered [36][37] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to bring apitegromab to patients [40][42] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, considering the data from previous trials [62] Question: What are the expectations for time to profitability? - Management expects a typical rare disease revenue trajectory leading to profitability within two to three years from launch, depending on pipeline progress [91]

Financial Data and Key Metrics Changes - For the fourth quarter of 2025, the company reported operating expenses of $91.9 million, which included $90.4 million in non-cash stock-based compensation. Excluding stock-based compensation, operating expenses were $72.5 million [26] - For the year ended 2025, total operating expenses were $384.6 million, including $75.6 million in non-cash stock-based compensation, leading to adjusted operating expenses of $309 million [27] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [11][27] Business Line Data and Key Metrics Changes - The company is focused on the launch of apitegromab, the world's first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [4][11] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase 1 studies [10][20] Market Data and Key Metrics Changes - The global market for SMA therapies is currently valued at nearly $5 billion in annual sales, with a significant unmet need for muscle-targeted therapies [21] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [22] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [4][12] - The company is building a 50-country operating platform in Europe and enhancing its commercial capabilities to support the launch of apitegromab [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, reaffirming guidance for BLA resubmission and U.S. launch in 2026 [7][29] - The company remains focused on long-term shareholder value while navigating the complexities of regulatory approvals and market readiness [28][91] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D priorities, with immediate access to $100 million [11][28] - The company is preparing for a supplemental BLA submission for a second fill-finish facility later in 2026 [14][27] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management confirmed that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [33][34] Question: What happens if the backup facility is needed? - Management indicated that whether it is a supplemental BLA or a fallback to the backup facility, they do not expect significant delays in timelines [36][37] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to progress the apitegromab file [40][42] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, considering the comprehensive data already presented [62] Question: What are the expectations for the launch trajectory? - Management expects robust demand for apitegromab but acknowledges potential access speed bumps due to payer reimbursement processes [69] Question: Will the MAA review be affected by the Catalent facility? - Management confirmed that progress with the FDA will positively influence the MAA review process with the EMA [81][82]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported operating expenses of $91.9 million, including $90.4 million in non-cash stock-based compensation, while excluding stock-based compensation, operating expenses were $72.5 million [24] - For the full year 2025, operating expenses totaled $384.6 million, with $75.6 million in non-cash stock-based compensation, and $309 million when excluding stock-based compensation [25] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [9][25] Business Line Data and Key Metrics Changes - The company is focused on the commercial launch of apitegromab, the first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [6][19] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase 1 studies [8][18] Market Data and Key Metrics Changes - The global market for SMA therapies is currently valued at nearly $5 billion in annual sales, with a significant unmet need for muscle strength and motor function treatments [20] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [21] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [3][10] - The company is building a 50-country operating platform in Europe and preparing for a launch in Germany in the second half of 2026 [10][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, anticipating a successful BLA resubmission following a reinspection of the Catalent Indiana facility [5][11] - The company remains focused on its strategic priorities and is optimistic about the transformative potential of its therapies for patients with SMA and other neuromuscular diseases [10][28] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D activities, with $100 million immediately available for use [25][27] - The company is also planning to monetize a Priority Review Voucher to further strengthen its balance sheet [27] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management confirmed that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [31][32] Question: What would happen if the backup facility is needed? - Management indicated that whether it is a supplemental BLA or a primary filing, they do not expect significant delays in timelines [34][36] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to bring apitegromab to patients [38][40] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, given the progress made during the original review process [60] Question: What are the expectations for time to profitability? - Management indicated that they expect a typical rare disease revenue trajectory, leading to profitability within two to three years from launch [91]

Regulatory Approval and Compliance - The regulatory approval process for apitegromab in the U.S. and EU is lengthy and unpredictable, with a Complete Response Letter (CRL) received from the FDA in September 2025 requiring resubmission of the Biologics License Application (BLA) [350]. - The CRL has delayed progress toward potential commercialization of apitegromab, impacting the ongoing regulatory review of the Marketing Authorization Application (MAA) by the EMA [352]. - Changes or disruptions at the FDA and other regulatory agencies could negatively impact the timely review and approval of the BLA upon resubmission [358]. - The company may face challenges in reaching agreements with regulatory authorities on clinical trial designs, which could delay marketing approvals [363]. - Regulatory approvals for apitegromab may be subject to limitations on approved uses and requirements for post-market testing [401]. - The FDA may reevaluate the Orphan Drug Act, introducing uncertainty regarding future regulatory impacts on the company's business [387]. - The company must comply with extensive regulatory requirements, including cGMP regulations, which may result in significant costs and ongoing obligations [400]. - Compliance with Good Clinical Practice (GCP) requirements is essential, and any failure could result in unreliable clinical data and regulatory scrutiny [379]. - The company is conducting clinical trials for apitegromab, including a long-term extension trial (ONYX) and a Phase 2 trial in children under two with SMA, which are subject to European privacy laws and the GDPR [460]. - The GDPR imposes fines of up to €20 million (approximately $21.5 million) or up to 4% of total worldwide annual turnover for serious offenses, increasing compliance costs and legal risks [460]. - The company faces potential civil, criminal, and administrative penalties for non-compliance with health care privacy and data protection laws, which could negatively affect operating results [459]. - The evolving regulatory landscape regarding data protection, particularly between the UK and EEA, may increase legal risk and complexity for the company [462]. - The company must comply with various state laws in the U.S. that may be more stringent than federal laws, such as the CCPA, which imposes comprehensive privacy rights and obligations [465]. Financial Performance and Capital Needs - The company has incurred net losses every year since inception and anticipates continued net losses in the future [346]. - The company will require additional capital to fund operations and complete the development and commercialization of apitegromab and other product candidates [348]. - The company's future financial performance and ability to commercialize apitegromab, if approved, will depend on effectively managing growth activities [434]. - Coverage and reimbursement for apitegromab, if approved, are uncertain and critical for profitability, as third-party payors may not provide adequate reimbursement [486]. - Changes in healthcare legislation and regulatory initiatives could limit reimbursement amounts, impacting demand for pharmaceutical products [491]. - The company may face substantial civil and criminal penalties for failing to comply with international business laws, including potential suspension from government contracting [475]. Clinical Development and Trials - Clinical development is expensive and can take many years, with inherent uncertainties leading to potential delays in trials and regulatory approvals [362]. - The company anticipates that future trials may utilize an open-label design, which could introduce biases affecting the perceived efficacy of treatments [365]. - Delays in clinical testing or marketing approvals could significantly increase product development costs and shorten exclusive commercialization periods [366]. - The company is developing apitegromab for FSHD, a rare disease affecting approximately 30,000 people in the U.S. and Europe, which may complicate patient enrollment in clinical trials [374]. - Difficulties in patient enrollment could lead to increased costs and adversely affect the timing or outcomes of clinical trials [375]. - The company relies heavily on third parties for conducting clinical trials, which may lead to delays if these parties do not meet their contractual obligations [376]. - Interim results from clinical trials are subject to change as more data becomes available, which could impact the perceived success of the trials [371]. - The results from preclinical studies and early-stage trials may not predict future outcomes, leading to potential setbacks in later-stage trials [372]. - The company may encounter delays in clinical trials due to reliance on third-party CROs, which could materially impact development timelines [382]. Market and Competitive Landscape - The biopharmaceutical industry is highly competitive, with many companies having greater resources and experience, which could impact the commercial opportunity for apitegromab [413]. - Market acceptance of apitegromab is uncertain, and failure to achieve sufficient acceptance could adversely affect revenue generation and profitability [407]. - Apitegromab's efficacy and safety have been demonstrated in clinical trials, with competitive pricing and market introduction timing being critical factors for its success [411]. - The company may face challenges in establishing sales and marketing capabilities or entering agreements with third parties for apitegromab commercialization [409]. - The company faces significant competition in securing partnerships, and recent business combinations among large pharmaceutical companies have reduced potential collaborators [508]. Intellectual Property and Legal Risks - The patenting process is complex and costly, and failure to secure adequate patent protection could allow competitors to develop similar products [510]. - Noncompliance with patent maintenance requirements could result in the loss of patent rights, impacting the company's market position [517]. - The ongoing conflict in Ukraine may create uncertainties regarding patent protection and enforcement in the region, potentially allowing competitors to enter the market [518]. - The company is dependent on third-party licensed intellectual property, and failure to comply with license obligations could result in significant rights loss [521]. - The company may face challenges in maintaining and prosecuting in-licensed patents, which could impact the validity and enforceability of these rights [522]. - Disputes with licensors regarding intellectual property could impair the company's ability to develop and commercialize product candidates [523]. - The company may struggle to obtain necessary rights for future product candidates, which could hinder business growth [524]. - The company may need to provide companion diagnostic tests for product candidates, which could be covered by third-party intellectual property rights [527]. - The competitive landscape for acquiring third-party intellectual property rights may disadvantage the company compared to more established firms [529]. - Changes in patent law could diminish patent value and impair the company's ability to protect its products [530]. - Third-party claims of intellectual property infringement could delay product development and result in costly litigation [536]. Operational and Management Challenges - The company relies on third-party manufacturers for clinical and commercial supplies, which may lead to risks related to supply limitations or quality issues [348]. - The company expects to invest significant resources to establish compliance, medical affairs, and commercial organizations for marketing apitegromab, if approved [356]. - The company expects to hire additional personnel to support the commercialization of apitegromab as it approaches market readiness [433]. - Attracting and retaining qualified management and scientific personnel is critical, as competition in the biopharmaceutical space is intense, potentially increasing costs [438]. - Changes in executive or senior management could disrupt business operations and adversely affect financial condition and results [439]. - Cybersecurity risks are heightened due to reliance on third-party IT systems, which could lead to material disruptions in development programs [441]. - Economic uncertainty, high inflation, and geopolitical instability may adversely affect the company's business and supply chains [429]. Collaboration and Partnership Risks - The company may seek collaborations for product candidates like apitegromab, but failure to secure such partnerships could adversely affect business operations [503]. - Collaborations may pose risks, including potential delays in clinical trials and insufficient funding for development programs [505].